Fresenius Medical Care North America
Medical Literature Bibliography* 2000 - 2010
*Includes work done from the FMCNA patient database over the past decade and work performed by
FMCNA-affiliated authors since 2000. Last updated August 19, 2010 from PubMed.
1.
MATSUO K, HAKIM RM, et al: Transforming growth factor- is involved in the pathogenesis of
dialysis-related amyloidosis (DRA). KI, Vol. 57, pp 697-708, 2000.
2.
HAKIM, RM: Clinical implications of biocompatibility in blood purification membranes.
Nephrol Dial Transplant (2000) 15 [Suppl 2]: pp 16-20.
3.
GOTCH FA. Kt/V is the best dialysis dose parameter. Blood Purif. 2000;18(4):276-85.
4.
LOWRIE EG. The normalized treatment ratio (Kt/V) is not the best dialysis dose parameter. Blood
Purif. 2000;18(4):286-94.
5.
GOTCH FA. Urea is the best molecule to target adequacy of peritoneal dialysis. Perit Dial Int.
2000;20 Suppl 2:S58-64.
6.
OFSTHUN NJ. Limitations of membrane structure and dialyzer design on large solute removal in
dialysis. Blood Purif. 2000;18(4):264-6.
7.
DIAZ-BUXO JA. Continuous cycling peritoneal dialysis, PD plus, and high-flow automated
peritoneal dialysis: a spectrum of therapies. Perit Dial Int. 2000;20 Suppl 2:S93-7.
8.
DIAZ-BUXO JA, CRUZ C, GOTCH FA. Advances in end-stage renal diseases 2000. Continuousflow peritoneal dialysis. preliminary results. Blood Purif. 2000;18(4):361-5.
9.
DIAZ-BUXO JA, CRAWFORD TL. Peritonitis and antibiotic therapy in patients on cycler
peritoneal dialysis--an update. Adv Perit Dial. 2000;16:229-32.
10.
SHALDON S, LAZARUS JM, LUNDIN AP, TZAMAIOUKAS AH, OREOPOULOS OG,
KJELLSTRAND CM. How can survival of the well-dialyzed patient be increased? Semin Dial.
2000 Jan-Feb;13(1):11-22.
11.
DIAZ-BUXO JA, LOWRIE EG, LEW NL, ZHANG H, LAZARUS JM. Quality-of-life evaluation
using Short Form 36: comparison in hemodialysis and peritoneal dialysis patients. Am J Kidney
Dis. 2000 Feb;35(2):293-300.
1
12.
DIAZ-BUXO JA. Early referral and selection of peritoneal dialysis as a treatment modality.
Nephrol Dial Transplant. 2000 Feb;15(2):147-9.
13.
CHERTOW GM, JOHANSEN KL, LEW N, LAZARUS JM, LOWRIE EG. Vintage, nutritional
status, and survival in hemodialysis patients. Kidney Int. 2000 Mar;57(3):1176-81.
14.
WINGARD RL, HAKIM RM: An evolving partnership: the role of the Centers for Disease
Control in the dialysis community. Semin Dial, 2000 Mar-Apr; 13(2), pp 71-74.
15.
LI Z, LEW NL, LAZARUS JM, LOWRIE EG. Comparing the urea reduction ratio and the urea
product as outcome-based measures of hemodialysis dose. Am J Kidney Dis. 2000 Apr;35(4):598605.
16.
SANDS JJ, NUDO SA, ASHFORD RG, MOORE KD, ORTEL TL. Antibodies to topical bovine
thrombin correlate with access thrombosis. Am J Kidney Dis. 2000 May;35(5):796-801.
17.
BERGSTROM J, LINDHOLM B, LACSON E JR, OWEN W JR, LOWRIE EG, GLASSOCK RJ,
IKIZLER TA, WESSELS FJ, MOLDAWER LL, WANNER C, ZIMMERMANN J. What are the
causes and consequences of the chronic inflammatory state in chronic dialysis patients? Semin
Dial. 2000 May-Jun;13(3):163-75.
18.
DIAZ-BUXO JA. The present and the future of APD. Automated Peritoneal Dialysis. Clin
Nephrol. 2000 Jun;53(6):411-6.
19.
NEYRA NR, HAKIM RM, SHYR Y, IKIZLER TA: Serum transferrin and serum prealbumin are
early predictors of serum albumin in chronic hemodialysis patients. J. Ren Nutr, October 2000;
10(4), pp. 184-190.
20.
NISSENSON AR, LAZARUS JM, LINDENFELD SM, HAKIM RM, BANDER SJ: The current
and future state of the ESRD program: a provider roundtable. Semin Nephrol 2000 Nov; 20(6): pp
543-555.
21.
SANDS JJ. Increasing AV fistulas: revisiting a time-tested solution. Semin Dial. 2000 NovDec;13(6):351-3.
22.
CHERTOW GM, ACKERT K, LEW NL, LAZARUS JM, LOWRIE EG. Prealbumin is as
important as albumin in the nutritional assessment of hemodialysis patients. Kidney Int. 2000
Dec;58(6):2512-7.
23.
MCCARLEY P, WINGARD RL, SHYR Y, PETTUS W, HAKIM RM, IKIZLER TA: Vascular
access blood flow monitoring reduces access morbidity and costs. KI, Vol.60 (2001), pp. 11641172.
2
24.
DIAZ-BUXO JA, CRAWFORD TL, BAILIE GR. Peritonitis in automated peritoneal dialysis:
antibiotic therapy and pharmacokinetics. Perit Dial Int. 2001;21 Suppl 3:S197-201.
25.
GOTCH FA. Daily hemodialysis is a complex therapy with unproven benefits. Blood Purif.
2001;19(2):211-6.
26.
RONCO C, DIAZ-BUXO JA. Automated peritoneal dialysis. Revisitation of the past or beginning
of a new PD era? Nephron. 2001 Jan;87(1):1-7.
27.
HAKIM RM, IKIZLER TA: Use of vascular access blood flow to evaluate vascular access. Am J
Kidney Dis 2001 Feb, 37: pp 451-452.
28.
SZCZECH LA, LOWRIE EG, LI Z, LEW NL, LAZARUS JM, OWEN WF JR. Changing
hemodialysis thresholds for optimal survival. Kidney Int. 2001 Feb;59(2):738-45.
29.
LACSON E JR, TENG M, LAZARUS JM, LEW N, LOWRIE E, OWEN W. Limitations of the
facility-specific standardized mortality ratio for profiling health care quality in dialysis. Am J
Kidney Dis. 2001 Feb;37(2):267-75.
30.
GOTCH FA. Is Kt/V Urea a Satisfactory Measure for Dosing the Newer Dialysis Regimens?
Semin Dial. 2001 Feb;14(1):15-17.
31.
FLETES R, LAZARUS JM, GAGE J, CHERTOW GM. Suspected iron dextran-related adverse
drug events in hemodialysis patients. Am J Kidney Dis. 2001 Apr;37(4):743-9.
32.
DIAZ-BUXO JA. Continuous flow peritoneal dialysis. Nephrol News Issues. 2001 May;15(6):1821.
33.
KARNIK JA, YOUNG BS, LEW NL, HERGET M, DUBINSKY C, LAZARUS JM, CHERTOW
GM. Cardiac arrest and sudden death in dialysis units. Kidney Int. 2001 Jul;60(1):350-7.
34.
GOTCH FA. Evolution of the single-pool urea kinetic model. Semin Dial. 2001 JulAug;14(4):252-6.
35.
LACSON E JR, DIAZ-BUXO JA. Daily and nocturnal hemodialysis: how do they stack up? Am J
Kidney Dis. 2001 Aug;38(2):225-39.
36.
SANDS JJ, NUDO SA, MOORE KD, ORTEL TL. Antibodies to prothrombin, factor V, and
beta2-glycoprotein I and vascular access thrombosis. ASAIO J. 2001 Sep-Oct;47(5):507-10.
3
37.
CRUZ C, MELENDEZ A, GOTCH FA, FOLDEN T, CRAWFORD TL, DIAZ-BUXO JA. Singlepass continuous flow peritoneal dialysis using two catheters. Semin Dial. 2001 Sep-Oct;14(5):3914.
38.
AMERLING R, DESIMONE L, INCIONG-REYES R, PANGILINAN A, FOLDEN T, RONCO
C, GOTCH FA, LEVIN N. Clinical experience with continuous flow and flow-through peritoneal
dialysis. Semin Dial. 2001 Sep-Oct;14(5):388-90.
39.
DIAZ-BUXO JA. Evolution of continuous flow peritoneal dialysis and the current state of the art.
Semin Dial. 2001 Sep-Oct;14(5):373-7.
40.
GOTCH FA. Kinetic modeling of continuous flow peritoneal dialysis. Semin Dial. 2001 SepOct;14(5):378-83.
41.
SAADEH E, IKILER TA, SHYR Y, HAKIM R, HIMMELFARB J: Recombinant Human Growth
Hormone in Patients with Acute Renal Failure, Journal of Renal Nutrition, Vol 11, No 4, pp 212219, October 2001.
42.
DIAZ-BUXO JA, LACSON E JR. Daily hemodialysis: a dialysis provider perspective. Adv Ren
Replace Ther. 2001 Oct;8(4):280-5.
43.
LOWRIE EG, TENG M, LACSON E, LEW N, LAZARUS JM, OWEN WF. Association between
prevalent care process measures and facility-specific mortality rates. Kidney Int. 2001
Nov;60(5):1917-29.
44.
DIAZ-BUXO JA, PASSLICK-DEETJEN J, GOTLOIB L. Potential hazards of polyglucose.
ASAIO J. 2001 Nov-Dec;47(6):602-7.
45.
LACSON E JR, DIAZ-BUXO JA. The treatment of anemia in peritoneal dialysis patients. Clin
Nephrol. 2001 Dec;56(6):415-27.
46.
HIMMELFARB J, EVANSON J, HAKIM RM, FREEDMAN S, SHYR Y, IKIZLER TA: Urea
volume of distribution exceeds total body water in patients with acute renal failure, KI, Vol. 61
(2002), pp. 317-323.
47.
CAGLAR K, FEDJE L, DIMMITT R, HAKIM RM, SHYR Y, IKIZLER TA: Therapeutic effects
of oral nutritional supplementation during hemodialysis, KI, Vol. 62 (2002), pp. 1054-1059.
48.
HIMMELFARB J, STENVINKEL P, IKIZLER TA, HAKIM RM: The elephant in uremia:
Oxidant stress as a unifying concept of cardiovascular disease in uremia, KI, Vol 62:5 (2002),
pp.1524-1538.
4
49.
GOTCH FA. On-line clearance: advanced methodology to monitor adequacy of dialysis at no cost.
Contrib Nephrol. 2002;(137):268-71.
50.
DIAZ-BUXO JA, CRAWFORD TL. Peritonitis in continuous cycling peritoneal dialysis. Adv
Perit Dial. 2002;18:161-4.
51.
DIAZ-BUXO JA. Streaming, mixing, and recirculation: role of the peritoneal access in continuous
flow peritoneal dialysis (clinical considerations). Adv Perit Dial. 2002;18:87-90.
52.
DIAZ-BUXO JA. Continuous flow peritoneal dialysis: clinical applications. Blood Purif.
2002;20(1):36-9.
53.
IKIZLER TA, PUPIM LB, BROUILLETTE JR, LEVENHAGEN DK, FARMER K, HAKIM RM,
FLAKOLL PJ: Hemodialysis stimulates muscle and whole body protein loss and alters substrate
oxidation, Am J Physiol Endocrinol Metab, 2002 Jan; 282 (1) E107-16.
54.
O'SHEA SI, SANDS JJ, NUDO SA, ORTEL TL. Frequency of anti-heparin-platelet factor 4
antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. Am
J Hematol. 2002 Jan;69(1):72-3.
55.
KLASSEN PS, LOWRIE EG, REDDAN DN, DELONG ER, COLADONATO JA, SZCZECH
LA, LAZARUS JM, OWEN WF JR. Association between pulse pressure and mortality in patients
undergoing maintenance hemodialysis. JAMA. 2002 Mar 27;287(12):1548-55.
56.
SANDS JJ, FERRELL LM, PERRY MA. Systemic barriers to improving vascular access
outcomes. Adv Ren Replace Ther. 2002 Apr;9(2):109-15.
57.
SANDS JJ. There is no "I" in "team": improving vascular access outcomes is a collaborative
effort. Nephrol News Issues. 2002 May;16(6):52-3.
58.
SPUHLER CL, SCHWARZE KD, SANDS JJ. Increasing AV fistula creation: the Akron
experience. Nephrol News Issues. 2002 May;16(6):44-7, 50, 52.
59.
SANDS JJ, FERRELL LM, PERRY MA. The role of color flow Doppler ultrasound in dialysis
access. Semin Nephrol. 2002 May;22(3):195-201.
60.
LOWRIE EG. Chronic inflammation and clinical outcome in adult hemodialysis patients. Kidney
Int Suppl. 2002 May;(80):94-8.
61.
PUPIN LB, KENT P, CAGLAR K, SHYR Y, HAKIM RM, IKIZLER TA: Improvement in
nutritional parameters after initiation of chronic hemodialysis, AM J KID DIS, Vol 40 (1), Jul
2002, pp. 143-51.
5
62.
PUPIM LB, FLAKOLL PJ, BROUILLETTE JR, LEVENHAGEN DK, HAKIM RM, IKIZLER
TA: Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic
hemodialysis patients, J. Clin. Invest., August 2002, Vol. 110, No. 4, pp. 483-492.
63.
IKIZLER TA, MORROW JD, ROBERTS LJ, EVANSON JA, BECKER B, HAKIM RM, SHYR
Y, HIMMELFARB J: Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients.
Clin Nephrol, Vol 58 (3), Sep 2002, pp. 190-7.
64.
CAGLAR K, PENG Y, PUPIM LB, FLAKOLL PJ, LEVENHAGEN D, HAKIM RM, IKIZLER
TA: Inflammatory signals associated with hemodialysis, KI, Vol 62 (4), Oct 2002, pp. 1408-16.
65.
CAGLAR K, HAKIM RM, IKIZLER TA: Approaches to the reversal of malnutrition,
inflammation, and atherosclerosis in end-stage renal disease, Nutr Rev Vol. 60 (11), Nov 2002, pp.
378-87.
66.
LOWRIE EG, LI Z, OFSTHUN N, LAZARUS JM. Body size, dialysis dose and death risk
relationships among hemodialysis patients. Kidney Int. 2002 Nov;62(5):1891-7.
67.
DIAZ-BUXO JA. The future of APD. Semin Dial. 2002 Nov-Dec;15(6):437-9.
68.
GOTCH FA. The kinetic spectrum of APD. Semin Dial. 2002 Nov-Dec;15(6):393-6.
69.
SANDS JJ, PERRY MA. Improving vascular access outcomes: a systems approach to eliminating
structural barriers. Blood Purif. 2003;21(1):111-7.
70.
GOTCH FA, LEVIN NW. Daily dialysis: the long and the short of it. Blood Purif. 2003;21(45):271-81.
71.
DIAZ-BUXO JA. What is the role of automated peritoneal dialysis and continuous flow peritoneal
dialysis? Contrib Nephrol. 2003;(140):264-71.
72.
DIAZ-BUXO JA. Solution formulation for continuous flow peritoneal dialysis. Contrib Nephrol.
2003;(140):309-17.
73.
LACSON E JR, OFSTHUN N, LAZARUS JM. Effect of variability in anemia management on
hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003 Jan;41(1):111-24.
74.
LOWRIE EG, TENG M, LEW NL, LACSON EJ, LAZARUS JM, OWEN WF. Toward a
continuous quality improvement paradigm for hemodialysis providers with preliminary
suggestions for clinical practice monitoring and measurement. Hemodial Int. 2003 Jan 1;7(1):2851.
6
75.
NEYRA R, CHEN KY, SUN M, SHYR Y, HAKIM RM, IKIZLER TA: Increased resting energy
expenditure in patients with end-stage renal disease, JPEN J Parenter Enteral Nutr, Vol 27 (1),
Jan-Feb 2003, pp. 36-42.
76.
OFSTHUN N, LABRECQUE J, LACSON E, KEEN M, LAZARUS JM. The effects of higher
hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 2003
May;63(5):1908-14.
77.
KNIGHT EL, OFSTHUN N, TENG M, LAZARUS JM, CURHAN GC. The association between
mental health, physical function, and hemodialysis mortality. Kidney Int. 2003 May;63(5):184351.
78.
LOWRIE EG, CURTIN RB, LEPAIN N, SCHATELL D. Medical outcomes study short form-36:
a consistent and powerful predictor of morbidity and mortality in dialysis patients. Am J Kidney
Dis. 2003 Jun;41(6):1286-92.
79.
REDDAN DN, KLASSEN PS, SZCZECH LA, COLADONATO JA, O'SHEA S, OWEN WF JR,
LOWRIE EG. White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol
Dial Transplant. 2003 Jun;18(6):1167-73.
80.
BOSCH J, HAKIM RM, LAZARUS JM, MCALLISTER CJ: Quality of care in profit vs not-forprofit dialysis centers, JAMA, Vol 289 (23), Jun 18 2003, pp. 3087-8.
81.
SANDS JJ. A review of vascular access monitoring techniques: what works best? Nephrol News
Issues. 2003 Jul;17(8):86-7.
82.
SANDS JJ, TATAREK M, UPDYKE D. What is the role of access monitoring in the dialysis
clinic? Nephrol News Issues. 2003 Jul;17(8):69, 72-6, 81.
83.
TENG M, WOLF M, LOWRIE E, OFSTHUN N, LAZARUS JM, THADHANI R. Survival of
patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003 Jul
31;349(5):446-56.
84.
SZCZECH LA, REDDAN DN, KLASSEN PS, COLADONATO J, CHUA B, LOWRIE EG,
LAZARUS JM, OWEN WF JR. Interactions between dialysis-related volume exposures,
nutritional surrogates and mortality among ESRD patients. Nephrol Dial Transplant. 2003
Aug;18(8):1585-91.
85.
DIAZ-BUXO JA. How much peritoneal dialysis is needed for optimal outcomes? Semin Dial.
2003 Sep-Oct;16(5):372-3.
86.
PUPIM LB, EVANSON JA, HAKIM RM, IKIZLER TA: The extent of uremic malnutrition at the
7
time of initiation of maintenance hemodialysis is associated with subsequent hospitalization. J. of
Renal Nutrition, October 2003, Vol. 13, No. 4, pp. 259-66.
87.
HIMMELFARB J, HAKIM RA: Oxidative stress in uremia, Curr Opin Nephrol Hypertens, Vol 12
(6), Nov 2003, pp. 593-8
88.
SANDS JJ, MONTIS AL, ETHEREDGE GD. Systemic barriers to vascular access care:
implications for clinical outcomes. Contrib Nephrol. 2004;142:350-62.
89.
DIAZ-BUXO JA. Maximizing biocompatibility: what is on the horizon? Adv Perit Dial.
2004;20:163-5.
90.
DIAZ-BUXO JA. Continuous-flow peritoneal dialysis: update. Adv Perit Dial. 2004;20:18-22.
91.
IKIZLER TA, SEZER MT, FLAKOLL PJ, HARIACHAR S, KANAGASUNDARAM NS,
GRITTER N, KNIGHTS S, SHYR Y, PAGANINI E, HAKIM RM: Urea space and total body
water measurements by stable isotopes in patients with acute renal failure, KI, Vol 65 (2) Feb
2004: pp. 725-32.
92.
SCHLAEPER C, DIAZ-BUXO JA. The Fresenius Medical Care home hemodialysis system.
Semin Dial. 2004 Mar-Apr;17(2):159-61.
93.
FELDMAN HI, JOFFE M, ROBINSON B, KNAUSS J, CIZMAN B, GUO W, FRANKLINBECKER E, FAICH G. Administration of parenteral iron and mortality among hemodialysis
patients. J Am Soc Nephrol. 2004 Jun;15(6):1623-32.
94.
GOTCH FA, PANLILIO FM, BUYAKI RA, WANG EX, FOLDEN TI, LEVIN NW. Mechanisms
determining the ratio of conductivity clearance to urea clearance. Kidney Int Suppl. 2004
Jul;(89):S3-S24.
95.
BLOCK GA, KLASSEN PS, LAZARUS JM, OFSTHUN N, LOWRIE EG, CHERTOW GM.
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol.
2004 Aug;15(8):2208-18.
96.
LOWRIE EG, LI Z, OFSTHUN N, LAZARUS JM. Reprocessing dialysers for multiple uses:
recent analysis of death risks for patients. Nephrol Dial Transplant. 2004 Nov;19(11):2823-30.
Epub 2004 Aug 17.
97.
PILLON L, PICCOLI A, LOWRIE EG, LAZARUS JM, CHERTOW GM. Vector length as a
proxy for the adequacy of ultrafiltration in hemodialysis. Kidney Int. 2004 Sep;66(3):1266-71.
98.
CRAWFORD-BONADIO TL, DIAZ-BUXO JA. Comparison of peritoneal dialysis solutions.
Nephrol Nurs J. 2004 Sep-Oct;31(5):499-507, 520.
8
99.
PUPIM LB, CAGLAR K, HAKIM RM, SHYR Y, IKIZLER, TA: Uremic malnutrition is a
predictor of death independent of inflammatory status, KI, Vol 66 (5), Nov 2004, pp. 2054-60.
100.
LOWRIE EG, LI Z, OFSTHUN N, LAZARUS JM. Measurement of dialyzer clearance, dialysis
time, and body size: death risk relationships among patients. Kidney Int. 2004 Nov;66(5):2077-84.
101.
LACSON E JR, LEVIN NW. C-reactive protein and end-stage renal disease. Semin Dial. 2004
Nov-Dec;17(6):438-48.
102.
SANDS JJ. Vascular access monitoring improves outcomes. Blood Purif. 2005;23(1):45-9.
103.
DIAZ-BUXO JA, CRAWFORD-BONADIO TL. Impact of peritoneal dialysis technology on
patient care. Adv Perit Dial. 2005;21:112-4.
104.
DIAZ-BUXO JA. Bicarbonate solutions: update. Adv Perit Dial. 2005;21:115-9.
105.
SCHLAEPER C, DIAZ-BUXO JA. Home hemodialysis and remote monitoring: current
technology, requirements and capabilities. Blood Purif. 2005;23(1):18-22.
106.
DIAZ-BUXO JA. Access and continuous flow peritoneal dialysis. Perit Dial Int. 2005 Feb;25
Suppl 3:S102-4.
107.
TENG M, WOLF M, OFSTHUN MN, LAZARUS JM, HERNAN MA, CAMARGO CA JR,
THADHANI R. Activated injectable vitamin D and hemodialysis survival: a historical cohort
study. J Am Soc Nephrol. 2005 Apr;16(4):1115-25. Epub 2005 Feb 23.
108.
DIAZ-BUXO JA. Beyond thrice-weekly hemodialysis. Hemodial Int. 2005 Jul;9(3):309-13.
109.
COLLINS AJ, BRENNER RM, OFMAN JJ, CHI EM, STUCCIO-WHITE N, KRISHNAN M,
SOLID C, OFSTHUN NJ, LAZARUS JM. Epoetin alfa use in patients with ESRD: an analysis of
recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis. 2005 Sep;46(3):4818.
110.
LOWRIE EG, LI Z, OFSTHUN N, LAZARUS JM. The online measurement of hemodialysis dose
(Kt): clinical outcome as a function of body surface area. Kidney Int. 2005 Sep;68(3):1344-54.
111.
LACSON E, TENG M, ONG J, VIENNEAU L, OFSTHUN N, LAZARUS JM. Antibody response
to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease. Hemodial
Int. 2005 Oct;9(4):367-75.
112.
LAZARUS JM, HAKIM RM, MADDUX FW, AMEDIA CA Jr.: The emperor has no clothes (but
9
has a catheter): a perspective on the state of chronic kidney disease care, Nephrol News Issues,
2005 Nov; 19(12): 45-6, 48.
113.
CHERTOW GM, GOLDSTEIN-FUCHS DJ, LAZARUS JM, KAYSEN GA. Prealbumin,
mortality, and cause-specific hospitalization in hemodialysis patients. Kidney Int. 2005
Dec;68(6):2794-800.
114.
DIAZ-BUXO JA. Clinical use of and experience with neutral-pH solutions. Adv Perit Dial.
2006;22:167-70.
115.
DIAZ-BUXO JA, CRAWFORD-BONADIO TL, ST PIERRE D, INGRAM KM. Establishing a
successful home dialysis program. Blood Purif. 2006;24(1):22-7.
116.
MISHLER R, SANDS JJ, OFSTHUN NJ, TENG M, SCHON D, LAZARUS JM. Dedicated
outpatient vascular access center decreases hospitalization and missed outpatient dialysis
treatments. Kidney Int. 2006 Jan;69(2):393-8.
117.
DIAZ-BUXO JA, WOODS HF. Protecting the endothelium: a new focus for management of
chronic kidney disease. Hemodial Int. 2006 Jan;10(1):42-8.
118.
DIAZ-BUXO JA. Complications of peritoneal dialysis catheters: early and late. Int J Artif Organs.
2006 Jan;29(1):50-8.
119.
LACSON E JR, LAZARUS JM. Dialyzer best practice: single use or reuse? Semin Dial. 2006
Mar-Apr;19(2):120-8.
120.
LOWRIE EG, LI Z, OFSTHUN NJ, LAZARUS JM. Evaluating a new method to judge dialysis
treatment using online measurements of ionic clearance. Kidney Int. 2006 Jul;70(1):211-7. Epub
2006 May 24.
121.
DIAZ-BUXO JA, LOREDO JP. Standard Kt/V: comparison of calculation methods. Artif Organs.
2006 Mar;30(3):178-85. Erratum in: Artif Organs. 2006 Jun;30(6):490.
122.
DIAZ-BUXO JA, GOTLOIB L. Peritoneal dialysis solutions--at a crossroad. Minerva Urol Nefrol.
2006 Jun;58(2):145-60.
123.
PULLIAM J, HAKIM RM, Lazarus JM: Peritoneal dialysis in large dialysis chains. Perit Dial Int.
2006 Jul-Aug; 26 (4): 435-7.
124.
LI Z, LACSON E JR, LOWRIE EG, OFSTHUN NJ, KUHLMANN MK, LAZARUS JM, LEVIN
NW. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J
Kidney Dis. 2006 Oct;48(4):606-15.
10
125.
WILLIAMS ME, LACSON E JR, TENG M, OFSTHUN N, LAZARUS JM. Hemodialyzed type I
and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int.
2006 Oct;70(8):1503-9. Epub 2006 Aug 30.
126.
KENNEY RJ, PIERRATOS A, PULLIAM JP. Dialyzing at home with the 2008K. Nephrol News
Issues. 2006 Oct;20(11):62, 64.
127.
LAZARUS JM, HAKIM RM: Translating Epoetin research into practice: the role of government
and the use of scientific evidence, Nephrol News Issues, 2006 Dec: 20(13); 12,22.
128.
WINGARD RL, PUPIM RB, KRISHNAN M, SHINTANI A, IKIZLER TA, HAKIM RM: Early
Intervention Improves Mortality and Hospitalization Rates in Incident Hemodialysis Patients:
RightStart Program, Clin J Am Soc Nephrol 2: 1170-1175, 2007
129.
LAZARUS JM, HAKIM RM: Dialysis facility ownership and Epoetin dosing in hemodialysis
patients: a dialysis provider’s perspective, Am J Kidney Dis, 2007 Sep; 30(3): pp. 366-70.
130.
LACSON EJR, LAZARUS JM, HIMMELFARB J, IKIZLER TA, HAKIM RM: Balancing
Fistula First with Catheters Last, Am J Kidney Dis., 2007 Sep; 50(3): pp. 395-95
131.
LACSON EJR, IKIZLER TA, LAZARUS JM, TENG M, HAKIM RM: Potential Impact of
Nutritional Intervention on End-Stage Renal Disease Hospitalization, Death, and Treatment Costs,
Journal of Renal Nutrition, Vol 17, No 6 (November), 2007: pp 363-372
132.
NESRALLAH GE, SURI RS, MOIST RM, OFSTHUN NJ, HAKIM RM, MCDONALD, S,
MARSHALL M, CARTER ST, RINDSAY RM: The international quotidian dialysis registry:
Annual report 2008, Hemodialysis International, 2008: 12: 281-289.
133.
BRADBURY BD, CRITCHLOW CW, WEIR MR, STEWART R, KRISHNAN M, HAKIM RM:
Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and
responsiveness in hemodialysis patients. Nephrol Dial Transplant (2008)
134.
HAKIM RM: Reducing early mortality in hemodialysis patients. Curr Opin Nephrol Hypertens
2008, 17: 595-599.
135.
LACSON E JR, LAZARUS JM, PANLILIO R, GOTCH F. Comparison of hemodialysis blood
access flow rates using online measurement of conductivity dialysance and ultrasound dilution.
Am J Kidney Dis. 2008 Jan;51(1):99-106.
136.
MADDUX FW, MADDUX DW, HAKIM RM: The role of the medical director: changing with
the times, Semin Dial, 2008 Jan-Feb;21(1) 54-7.
137.
HUNG A, PUPIM L, YU C, SHINTANI A, SIEW E, AYUS C, HAKIM RM, IKIZLER TA:
Determinants of C-reactive protein in chronic hemodialysis patients: Relevance of dialysis catheter
11
utilization, Hemodial Int. 2008 Apr; 12(2): 236-243.
138.
COSGROVE DO, CHAN KE. Renal transplants: what ultrasound can and cannot do. Ultrasound
Q. 2008 Jun;24(2):77-87; quiz 141-2. Review.
139.
CHAN KE, LAFAYETTE RA, WHITTEMORE AS, HLATKY MA, MORAN J. Facility factors
dominate the ability to achieve target haemoglobin levels in haemodialysis patients. Nephrol Dial
Transplant. 2008 Sep;23(9):2948-56. Epub 2008 May 9.
140.
LACSON E JR, ROGUS J, TENG M, LAZARUS JM, HAKIM RM: The association of race with
erythropoietin dose in patients on long-term hemodialysis. Am J Kidney Dis 2008 Dec; 52(6):
1104-14.
141.
WILLIAMS ME, LACSON E JR, TENG M, HAKIM RM, LAZARUS JM: Extremes of
Glycemic Control (HbA(1c)) Increase Hospitalization Risk in Diabetic Hemodialysis Patients in
the USA. Am J Nephrol. 2009;29(1):54-61. Epub 2008 Aug 8.
142.
LACSON EJ R, WANG W, HAKIM RM, TENG M, LAZARUS JM: Associates of Mortality and
Hospitalization in Hemodialysis: Potentially Actionable Laboratory Variables and Vascular
Access. Am J Kidney Dis 2009 Jan; 53(1) 79-90
143.
CHAN KE, LAZARUS JM, THADHANI R, HAKIM RM: Anticoagulant and Antiplatelet Usage
Associates with Mortality among Hemodialysis Patients. J Am Soc Nephrol 2009 Apr;20(4):82781.
144.
CAVANAUGH KL, WINGARD RL, HAKIM RM, ELASY TA, IKIZLER TA: Patient dialysis
knowledge is associated with permanent arteriovenous access use in chronic hemodialysis. Clin J
Am Soc Nephrol. 2009 May;4(5):905-6.
145.
GREENE T, DAUGIRDAS JT, DEPNER TA, GOTCH F, KUHLMAN M; FREQUENT
HEMODIALYSISNETWORK STUDY GROUP; NATIONAL INSTITUTE OF DIABETES AND
DIGESTIVE AND KIDNEYDISEASES; NATIONAL INSTITUTES OF HEALTH. Solute
clearances and fluid removal in the frequent hemodialysis network trials. Am J Kidney Dis. 2009
May;53(5):835-44.Epub 2009 Apr 1.
146.
FOLEY RN, HAKIM RM: Why is the Mortality of Dialysis Patients in the United States Much
Higher than the Rest of the World? J Am Soc Nephrol. 2009 Jul:20(7):1432-5
147.
SANDS JJ, LACSON E JR, OFSTHUN NJ, KAY JC, DIAZ-BUXO JA. Home hemodialysis: a
comparison of in-center and home hemodialysis therapy in a cohort of successful home
hemodialysis patients. ASAIO J. 2009 Jul-Aug;55(4):361-8.
148.
CHAN KE, LAZARUS JM, WINGARD RL, HAKIM RM. Association between repeat
hospitalization and early intervention in dialysis patients following hospital discharge. Kidney Int.
12
2009 Aug; 76(3):331-41
149.
HAKIM RM, IKIZLER TA. Anabolic interventions in ESRD: Light at the end of the tunnel? Am
J Kidney Dis. 2009 Aug; 54(2):201-4
150.
CHAN KE, LAZARUS JM, THADHANI R, HAKIM RM. Warfarin Use Associates with
Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation. J Am Soc Nephrol.
2009 Oct;20(10):2223-33. Epub 2009 Aug 27.
151.
SUNDELL MB, CAVANAUGH KL, WU P, SHINTANI A, HAKIM RM, IKIZLER TA. Oral
Protein Supplementation Alone Improves Anabolism in a Dose-Dependent Manner in Chronic
Hemodialysis Patients. J Ren Nutr, 2009 Sept; 19(5):412-21
152.
LACSON E JR, WANG W, LAZARUS JM, HAKIM RM: Hemodialysis Facility-Based Qualityof-Care Indicators and Facility-Specific Patient Outcomes. Am J Kidney Dis, 2009 Sept;
54(3):390-7.
153.
LACSON E JR, WANG W, LAZARUS JM, HAKIM RM. Change in Vascular Access and
Mortality in Maintenance Hemodialysis Patients. Am J Kidney Dis. 2009 Nov;54(5):912-21. Epub
2009 Sep 12.
154.
HAKIM RM, HIMMELFARB J. Hemodialysis access failure: A call to action—revisted. Kidney
Int. 2009 Nov; 76(10):1040-8.
155.
LACSON E Jr, XU J, LIN SF, DEAN SG, LAZARUS JM, HAKIM RM. A Comparison of SF-36
and SF-12 Composite Scores and Subsequent Hospitalization and Mortality Risks in Long-Term
Dialysis Patients. Clin J Am Soc Nephrol. 2009 Dec 17. [Epub ahead of print]
156.
WINGARD RL, CHAN KE, LAZARUS JM, HAKIM RM. The “right” of passage: surviving the
first year of dialysis. Clin J Am Soc Nephrol. 2009 Dec; 4 Suppl 1:S114-20.
157.
LACSON E JR, XU J, LIN SF, DEAN SG, LAZARUS JM, HAKIM R. Association between
achievement of hemodialysis quality-of-care indicators and quality-of-life scores. Am J Kidney
Dis. 2009 Dec;54(6):1098-107. Epub 2009 Sep 25.
158.
LACSON E Jr, WANG W, LESTER K, OFSTHUN N, LAZARUS JM, HAKIM RM. Outcomes
Associated with In-Center Nocturnal Hemodialysis from a Large Multicenter Program. Clin J Am
Soc Nephrol. 2010 Feb;5(2):220-6. Epub 2009 Dec 3.
159.
CHAN KE, THADHANI R, LAZARUS JM, HAKIM RM. Modeling the 4D Study: statins and
cardiovascular outcomes in long-term hemodialysis patients with diabetes. Clin J Am Soc
Nephrol. 2010 May;5(5):856-66. Epub 2010 Mar 25.
160.
CHAN KE, LAZARUS JM, HAKIM RM. Digoxin Associates with Mortality in ESRD. J Am Soc
Nephrol. 2010 Jun 24. [Epub ahead of print]
13
161.
CAVANAUGH KL, WINGARD RL, HAKIM RM, EDEN S, SHINTANI A, WALLSTON KA,
HUIZINGA MM, ELASY TA, ROTHMAN RL, IKIZLER TA. Low Health Literacy Associates
with Increased Mortality in ESRD. J Am Soc Nephrol. 2010 Jul 29. [Epub ahead of print]
162.
WILLIAMS ME, LACSON E JR, WANG W, LAZARUS JM, HAKIM R. Glycemic Control and
Extended Hemodialysis Survival in Patients with Diabetes Mellitus: Comparative Results of
Traditional and Time-Dependent Cox Model Analyses. Clin J Am Soc Nephrol. 2010 Jul 29.
[Epub ahead of print]
14